STNM 01

Drug Profile

STNM 01

Alternative Names: STNM-01

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Stelic Institute & Co
  • Developer Sameshima Hospital; Stelic Institute & Co
  • Class Anti-inflammatories; Antifibrotics; Antiulcers
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Clinical Phase Unknown Crohn's disease

Most Recent Events

  • 13 Jul 2016 Stelic Institute & Co. completes a phase II trial in Ulcerative colitis in Germany (EudraCT2012-004768-23)
  • 08 Feb 2016 Clinical trials in Ulcerative colitis and Crohn's disease (Treatment-experienced) in Japan (Submucosal) (UMIN000020900)
  • 18 Jul 2013 Preclinical development is ongoing in Crohn's disease stricture in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top